Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratympanic dexamethasone crossover trial for idiopathic sudden sensorineural hearing loss
ACTRN12622001555741Phase 4Recruiting
- Sponsor
- University of Melbourne
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dexamethasone and prednisolone in idiopathic sudden sensorineural hearing loss (ISSNHL) (2 arms), sponsored by University of Melbourne. Primary endpoint: Change in pure-tone hearing thresholds. Started Feb 2023; status: recruiting.
02
Drugs
dexamethasoneprednisolone
03
Conditions
idiopathic sudden sensorineural hearing loss (ISSNHL)
Beyond the preview
Go deeper on ACTRN12622001555741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001555741.